1982-87, Jinzhou Medical College, Jinzhou, P.R.C., M.D. , Medicine
1988-94, Medical College of Ohio, Toledo, Ohio, Ph.D., Pathology
1997-2002, UCSF, Staff Research Associate, Dept. of Surgery, UCSF Comprehensive Cancer Center
Thoracic Oncology Program
Thoracic Oncology Laboratory
UCSF Helen Diller Family Comprehensive Cancer Center
Akt Signaling Pathway
Human cancer genetics and epigenetics
Lung cancer and mesothelioma
Molecular analysis on matched normal/tumor tissues
Small molecules, antibodies and recombinant proteins
Wnt Signaling Pathway
Dr. Liang You received his M.D. in 1987 from the Jinzhou Medical College in China and his Ph.D. in pathology from the Medical College of Ohio in 1994. He began work at UCSF in the thoracic oncology laboratory after work at the National Cancer Institute. At UCSF, Dr. You has made a significant impact on lung cancer and mesothelioma research. Most notably, he has been been instrumental in helping Dr. David Jablons mold a fledgling research effort into a thriving molecular genomics laboratory, an integral part of the Comprehensive Cancer Center and nationally recognized.
In November 2007, Dr. You was presented with the David Jablons "Asclepios" Award by the Bonnie J. Addario Lung Cancer Foundation for his pioneering research.
Dr. You has been a creative and dynamic force in the lab and his work has led to numerous discoveries. He helped demonstrate the relationship of p14ARF tumor suppressor deletions to the p53 pathway in mesothelioma and the effects of oncolytic viruses upon these tumors. He also discovered several novel mechanisms for the activation of upstream WNT pathways.
Dr. You has helped identify several novel biomarkers and therapeutic targets in lung cancer and mesothelioma. He and his colleagues demonstrated overexpression of Dishevelled-3 and silencing of SFRP-2, SOCS-3 and WIF-1 through promoter methylation. Dr. You and chemist Dr. Naoaki Fujii developed a small molecule Wnt pathway inhibitor, FJ9, that disrupts the interaction between the Frizzled receptor and Dishevelled, a Wnt signal transducer.
Dr. You is currently investigating the use of recombinant human WIF-1 protein as a cancer therapy and seeking out new therapeutic targets and novel interventions.
Most recent publications from a total of 67
Hung MS, Chen IC, You L, Jablons DM, Li YC, Mao JH, Xu Z, Hsieh MJ, Lin YC, Yang CT, Liu ST, Tsai YH Hung MS, Chen IC, You L, Jablons DM, Li YC, Mao JH, Xu Z, Hsieh MJ, Lin YC, Yang CT, Liu ST, Tsai YH. Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells. Oncol Rep. 2015 Dec; 34(6):3187-95. View in PubMed
Yang YL, Ni J, Hsu PC, Mao JH, Hsieh D, Xu A, Chan G, Au A, Xu Z, Jablons DM, You L Yang YL, Ni J, Hsu PC, Mao JH, Hsieh D, Xu A, Chan G, Au A, Xu Z, Jablons DM, You L. Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma. J Cell Mol Med. 2015 Oct; 19(10):2385-96. View in PubMed
Wang Y, Xu Z, Mao JH, Hsieh D, Au A, Jablons DM, Li H, You L Wang Y, Xu Z, Mao JH, Hsieh D, Au A, Jablons DM, Li H, You L. PR-Set7 is Degraded in a Conditional Cul4A Transgenic Mouse Model of Lung Cancer. Zhongguo Fei Ai Za Zhi. 2015 Jun 20; 18(6):345-50. View in PubMed
Wang Y, Xu Z, Mao JH, Hung MS, Hsieh D, Au A, Jablons DM, You L Wang Y, Xu Z, Mao JH, Hung MS, Hsieh D, Au A, Jablons DM, You L. Analysis of lung tumor initiation and progression in transgenic mice for Cre-inducible overexpression of Cul4A gene. Thorac Cancer. 2015 Jul; 6(4):480-7. View in PubMed
Yeh CC, Fan Y, Jiang L, Yang YL, He B, You L, Mann M Yeh CC, Fan Y, Jiang L, Yang YL, He B, You L, Mann M. Genistein Suppresses Growth of Human Uterine Sarcoma Cell Lines via Multiple Mechanisms. Anticancer Res. 2015 Jun; 35(6):3167-73. View in PubMed
You B, Yang YL, Xu Z, Dai Y, Liu S, Mao JH, Tetsu O, Li H, Jablons DM, You L You B, Yang YL, Xu Z, Dai Y, Liu S, Mao JH, Tetsu O, Li H, Jablons DM, You L. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. Oncotarget. 2015 Feb 28; 6(6):4357-68. View in PubMed
Zhang S, Yang YL, Wang Y, You B, Dai Y, Chan G, Hsieh D, Kim IJ, Fang LT, Au A, Stoppler HJ, Xu Z, Jablons DM, You L Zhang S, Yang YL, Wang Y, You B, Dai Y, Chan G, Hsieh D, Kim IJ, Fang LT, Au A, Stoppler HJ, Xu Z, Jablons DM, You L. CK2a, over-expressed in human malignant pleural mesothelioma, regulates the Hedgehog signaling pathway in mesothelioma cells. J Exp Clin Cancer Res. 2014; 33(1):93. View in PubMed
Yang YL, Jablons D, You L Yang YL, Jablons D, You L. An alternative way to initiate Notch1 signaling in non-small cell lung cancer. Transl Lung Cancer Res. 2014 Aug; 3(4):238-41. View in PubMed
Yang YL, Hung MS, Wang Y, Ni J, Mao JH, Hsieh D, Au A, Kumar A, Quigley D, Fang LT, Yeh CC, Xu Z, Jablons DM, You L Yang YL, Hung MS, Wang Y, Ni J, Mao JH, Hsieh D, Au A, Kumar A, Quigley D, Fang LT, Yeh CC, Xu Z, Jablons DM, You L. Lung tumourigenesis in a conditional Cul4A transgenic mouse model. J Pathol. 2014 Jun; 233(2):113-23. View in PubMed
Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, LaBarge MA, You L, Kogan SC, Gray JW, Mao JH, Wei G Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, LaBarge MA, You L, Kogan SC, Gray JW, Mao JH, Wei G. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014 Jan 15; 74(2):520-31. View in PubMed
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.